Abstract: Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol, and methods of using the same for treating or inhibiting increased urinary urgency or urinary incontinence and/or pain.

Abstract: The invention relates to methods of modulating immune function, suppressing immune response, treating autoimmune diseases or autoimmune disorders, and treating diseases, sequelae or pathological conditions mediated by an activation of the immune system comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound.

Abstract: Combinations of synthetic low molecular weight catalysts for the dismutation of superoxide and Nonsteroidal Analgesic/Anti-Inflammatory Drugs (NSAIDs) are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions.

Abstract: The invention provides a process for preparing non-crystalline organic compositions and non-crystalline, co-amorphous blends of organic compounds.

Abstract: The present invention relates to new bisbenzisoselenazolonyl derivatives of the following general formula (I), wherein R is C4-5-alkylene, and their pharmaceutically acceptable salts. The inventive derivatives have antineoplastic, anti-inflammatory and antithrombotic activities.

Abstract: The invention relates to spheroids which are obtained using a method comprising the following steps consisting in: supplying an active principle of vegetable origin in an isolated form; supplying a solution of vegetable origin, containing the active principle or a precursor thereof; supplying an absorbing and adsorbing substance having plastic properties that are compatible with the method; mixing said different products and wetting the mixture with a wetting liquid; extruding the wet mixture; and forming spheroids through the spheronization of the extruded product. The invention also relates to sample applications such as artesunate-based antimalarial spheroids and aspring-based spheroids.

Abstract: The present invention relates to new bisbenzisoselenazolonyl derivatives of the following general formulae (I), (II) or (III) and their pharmaceutically acceptable salts. The inventive derivatives have antineoplastic, anti-inflammatory and antithrombotic activities.

Abstract: Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Abstract: It is intended to provide a composition having at least one effect among the following effects; a plurality of medicinal ingredients can be taken as one preparation and the convenience for patients is excellent; the drug compliance is excellent; the amount of jelly composition to be taken at a time is small; the release of an active ingredient in the digestive tract is excellent; the absorption of an active ingredient to the body is excellent; the storage stability of an active ingredient is excellent; the dispersibility of an active ingredient in the composition is excellent; the storage stability of the composition is excellent; the syneresis of the composition is less, it has an appropriate jelly strength to a degree that does not disintegrate during carrying and before taking and easily disintegrates after taking; the handleability during preparation of the composition is excellent; the portability of the composition is excellent; the feeling of taking the composition is excellent; it has an effect on red

Abstract: This invention relates to the use of combinations of a sodium channel blocking compound that binds to an SSI or SS2 site of extracellular region of a sodium channel alpha subunit, and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals. Pharmaceutical compositions based upon this invention can enhance analgesic effect and reduce dosage of aspirin, therefore side effects and adverse reactions are decreased accordingly.

Abstract: Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.

Abstract: This invention relates to an oral composition for treatment or prevention of atherosclerosis comprising a low-dose aspirin and a low-dose of statin wherein the aspirin and statin are in a slow-release formulation. The invention also relates to a method of treatment or prevention of atherosclerosis using such a composition.

Abstract: The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent.

Abstract: Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity of a user for the purpose of dissolving over a prolonged period of time and thereby delivering an essential oil component therein. In certain embodiments, the sustained release dosage form includes a beneficial agent and, therefore, not only provides for the prolonged delivery of an essential oil component to an oral cavity, but also provides for the sustained release of a beneficial agent thereto. In certain embodiments, the sustained release dosage form includes a biocompatible, water-insoluble polymer, e.g.

Abstract: The present invention comprises a method of achieving ingredient stabilization in a composition comprising the steps of: combining a pregelatinized starch with at least one sensitive ingredient; adsorbing said sensitive ingredient onto the pregelatinized starch; and wherein said sensitive ingredient is evenly distributed throughout said pregelatinized starch.

Abstract: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.

Abstract: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form a moistened, plasticized mass, frozen to below ?20° C. , and the water sublimed in high vacuum. In this way solid dosage forms are obtainable with a similar porous structure as usually result from freeze-drying processes, but the process requires much less water, which means considerably less time and less energy.

Abstract: The present invention overcomes limitations of the prior art by providing new compounds and methods for the treatment of conditions, such as neurodegenerative diseases (e.g., multiple sclerosis), psychiatric disorders (e.g., psychosis, bipolar disorder, depression, neuropathic pain), conditions involving CNS-mediated chronic pain, spinal cord injuries, and other diseases or injuries.

Abstract: The present invention provides to methods of preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder comprising administering to a subject in need thereof one or more integrin ?V?3 antagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder.

Abstract: A medical device having a lubricious coating on at least a section of the medical device, and a method of coating a medical device, the lubricious coating being a network of a hydrophilic compound cross-linked to itself and interlocked with a network of a cross-linked polymerized multifunctional monomer or polymer. The coating can include one or more agents which provide enhanced adhesion of the coating on the device, or which provide faster hydration of the coating and/or improved lubricity. Additionally, the lubricious coating can be provided with one or more therapeutic or diagnostic agents, and in one embodiment the agent elutes relatively quickly in a concentrated release from the lubricious coating upon hydration of the coating.

Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.

Abstract: Compositions for inhibiting vascular occlusion in humans comprising aspirin for inhibiting vascular occlusion which further contain nutritional supplements are disclosed. The compositions are provide in a dosage form that provides stability of the active ingredient allowing for improved shelf life. A further composition included a cholesterol-lowering agent in combination with aspirin and optionally with nutritional supplements.

Abstract: The present invention relates to novel thiosulfonates derivatives. The present invention also provides methods for preventing, treating and/or reducing inflammation-associated diseases in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous or cutaneous systems as well as infective and tumoral diseases employing said compounds.

Abstract: The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated.

Abstract: The invention concerns a composition containing red yeast rice and other components, as a chemopreventative agent to reduce the risk of cancer.

Abstract: Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.

Abstract: Method and systems of treating a patient with at least one of a myocardial infarction, a stroke, and a pulmonary embolism include providing a stimulator coupled to at least one electrode and a catheter, configuring one or more stimulation parameters to treat at least one of a myocardial infarction, a stroke, and a pulmonary embolism, programming the stimulator with the one or more stimulation parameters, delivering with the stimulator via the catheter at least one drug to at least one tissue in accordance with the one or more stimulation parameters, and limiting perfusion of the at least one tissue by delivering electrical stimulation with the stimulator via the at least one electrode to the at least one tissue.

Abstract: Methods of delaying the onset or treating the progression of Type 2 diabetes in subjects that have increased blood levels of an inflammation marker protein. In one embodiment, the method includes administering an inhibitor OF ?1-antitrypsin (AT) to the subject, and optionally co-administering an anti-diabetic medicament or anti-inflammatory agent to the subject. Treatment regimens provided by the invention may be used to delay the onset of or to control Type 2 diabetes. The invention provides for the use of an inhibitor of ?1-antitrypsin, such as gemfibrozil (GF), for the manufacture of a medicament for the uses described herein. The invention further provides combinations of agents for treating or delaying the progression or onset of diabetes, comprising an inhibitor of ?1-antitrypsin and an anti-inflammatory agent and/or an anti-diabetic medicament.

Abstract: Provided are beverages containing one or more anti-inflammatory agents, derivatives thereof, prodrugs thereof, salts thereof, or combinations thereof. Additional components include, but are not limited to, electrolytes, minerals, vitamins, flavorings, antacids, buffers, dissolution enhancers and solubility enhancers. Additionally, a beverage mix containing an anti-inflammatory agent is disclosed. Furthermore, a method for preventing or mitigating pain or soreness is disclosed.

Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

Abstract: The invention relates to a composition containing, preferably in a physiologically acceptable medium, at least one xanthine base or a plant extract containing it, at least one polyurethane powder, and at least one non-ionic dimethicone copolyol. The invention also relates to a cosmetic method for combating cellulite and/or “orange-peel” skin and/or slimming the figure, comprising the application of the composition to the skin. The composition applied to the skin exhibits good cosmetic properties of softness and of non-tackiness.

Abstract: Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective amount of a thrombin receptor antagonist, such as SCH 530348, to the patient. Administration of a loading dose of about 40 mg of SCH 530348 in as little as one hour prior to the procedure can result in therapeutically effective levels of platelet aggregation.

Abstract: The present invention relates to an improved method for treating a wide range of inflammatory disorders by administering a tetracycline compound together with an effective inhibitor of tetracycline absorption, such as polyvalent metals. Pharmaceutical compositions used in that method are also taught.

Abstract: The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.

Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

Abstract: Methods, compounds and compositions for the modulation of TGF-? are disclosed wherein the vascular permeability in a subject is altered. The compounds can be antagonists or agonists, and can be oligonucleotides, antisense oligonucleotides, small molecules, antibodies, and the like. Compounds that modulate TGF-?, regulate TGF-? bioavailabililty, or the configuration and context of type 1 collagen can be used for the treatment or prevention of diseases caused by vascular permeability.

Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.

Abstract: The present invention is based upon the surprising discovery that the offering aqueous composition according to the invention is capable of being used as topical nail hardener. The present invention relates to a nail hardener that employs a composition of glycerin and water in the preferred concentration as the active components, in a solvent carrier mixture from a group of pharmaceutically acceptable solvents such as ethanol and Propylene glycol.

Abstract: Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided.

Abstract: The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. This invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine.

Abstract: A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks that can lead to neurodegeneration as is seen in wet age-related macular degeneration (AMD), epilepsy and diabetes, in which an effective amount of a blood flow regulatory drug is administered to a subject in need of it. Illustrative blood flow regulatory drugs include anticoagulants and vasodilators, and their mixtures.

Abstract: Multifunctional, single, bilayer, and trilayer coated tablets for combination therapy are formed wherein the bioactive agents responsible for the therapeutic multifunctionality are present as a combination of a gastric acid-reducing agent, such as omeprazole and ranitidine, and at least one analgesic/anti-inflammatory agent, such as acetaminophen, naproxen sodium, ibuprofen, tolmetin, and aspirin.

Abstract: By providing a reusable support base or carrier which is constructed for being easily held by the user in the person's hand, and incorporating additives, therapeutic agents and/or medicinal components therein, a highly effective and easily employed, multi-purpose hand and/or skin cleaner, sanitizer, drug delivery, and exercise system is realized. Preferably, the support base or carrier is formed from soft, pliable, compressible and/or flexible material which is easily manipulated by the user in the person's hand or on the skin surface of other areas of the person's body. By employing selected additives or combinations thereof, a multi-purpose, highly effective, and unique hand or skin cleaning, sanitizing, and drug delivery system is realized in a system which also improves and enhances the individual's ability to obtain exercising of the hand.

Abstract: A method for screening for compounds or salts thereof, in particular nonsteroidal anti-inflammatory compounds or salts thereof, that are safe for gastric mucosa and cause little gastrointestinal side effects. The method uses a particular liposome to serve as a cell membrane model. The liposome encapsulates a fluorescent dye, in particular, calcein and is formed of phospholipids, such as phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, and phosphatidylinositol. A test compound is allowed to react with the liposome and the leakage of the fluorescent dye from the liposome is evaluated. As a result, compounds safe for gastric mucosa, in particular, anti-inflammatory compounds can be screened.

Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a plurality of particles in a matrix. The particles contain an active ingredient, such as ibuprofen, and a first water soluble acid having a solubility greater than about 10 g/100 mL water at 20° C.; and the matrix contains a second water soluble acid having a solubility less than about 5 g/100 mL water at 20° C.

Abstract: The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains of C. difficile, C. perfringens, or S. aureus.

Abstract: A combination of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.

Abstract: Product for the treatment of household pets as having need of a therapeutic treatment, characterised in that it comprises, in separate form and intended to be mixed: a non-foaming base suited to constituting a galenic form for topical application and/or dermatological treatment, and a concentrated preparation of at least one component with reduced biological activity and suited to acquiring a maximum biological activity in relation to the desired treatment, under the effect of an appropriate change to the pH, advantageously to pH 6-7, whereas said at least one activable component with reduced biological activity is itself premixed with at least one foaming agent and as an option at least one emulsifier in said concentrated preparation, and whereas the pH of said concentrated preparation is either less than around 5 or more than 8, with as an option adjustment to this value by means of an appropriate buffer.